Recognify’s schizophrenia drug fails mid-stage test Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 28 July, 2025

The biotech companies everyone will be talking about in 2025 get revealed live in Boston this September. Endpoints 11 isn’t just any list — it’s where industry insiders gather to see which bold bets might pay off. Find out who wins in real time at the State Room — reserve your spot now and save with the Early Bird rate.

news GSK sends $500M upfront to Hengrui in broad deal with China's leading pharma Celcuity posts Phase 3 win in breast cancer, setting up challenge to Novartis and Roche Recognify’s schizophrenia drug fails mid-stage test, backer atai’s stock dips Shanghai biotech VelaVigo snags $60M after landing two licensing deals FDA investigates death of boy who got Elevidys, Roche says it's unrelated to therapy

Principal - Life Science Alexandria Real Estate Equities San Francisco, CA, USA Senior Director of IT Caribou Biosciences, Inc. Berkeley, CA, USA Director Of Business Development, Health And Biomedical Innovation Brown University Providence, RI, USA Senior Patent Counsel Caribou Biosciences, Inc. Berkeley, CA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Aug 21 2:00pm ET Agentic AI is here: Real-world applications in life sciences & healthcare sponsored by IBM

Supply chain strategy just got more complicated — is your manufacturing model still viable? Trade tensions, policy shifts, and geopolitical uncertainty have biopharma executives rethinking manufacturing and distribution. How are the experts doing it now? Find out — get your spot today.

endpoints pharma FDA developing new flu vaccine framework to tackle 'problems,' senior official says CHMP backs Lilly’s Alzheimer’s drug in certain patients, Gilead’s twice-yearly HIV prevention shot, among others •  CHMP recommends against Elevidys in Europe, in another blow to the gene therapy FDA delays decision date on Bayer’s hot flash treatment by up to three months

in case you missed it 1. Updated: Bristol Myers snags Cristian Massacesi from AstraZeneca as its new chief medical officer 2. Pharma companies slow down their manufacturing projects in Ireland, data show 3. Peer Review Generate's head of R&D returns to Merck; Galapagos shuffles leadership team 4. Memo Therapeutics says there’s still a path forward for kidney transplant drug that failed Phase 2 trial 5. William J. Rutter, Biotech Pioneer of Gene-Based Medicine, Dies at 97 6.